Ruiqin Ma

Title: Ruiqin Ma - Innovator in Genetic Screening for Lung Carcinoma.

Introduction

Ruiqin Ma is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of genetic screening, particularly in the early detection of lung carcinoma. His innovative work focuses on the use of genetic markers to differentiate between benign and malignant pulmonary micro-nodules.

Latest Patents

Ruiqin Ma holds a patent for "Genetic markers used for identifying benign and malignant pulmonary micro-nodules and the application thereof." This patent presents a group of peripheral blood gene markers that are instrumental in screening for benign and malignant pulmonary micro-nodules. The gene sequences, characterized by micronodular lung carcinoma, exhibit differential expression in the peripheral blood of patients with and without micronodular lung carcinoma. The invention emphasizes the use of these gene markers for early screening, showcasing high sensitivity and strong specificity. The non-invasive nature of the blood test makes it particularly suitable for large-scale population screenings when combined with CT and other imaging examinations.

Career Highlights

Ruiqin Ma is associated with Shanghai Biomedical Laboratory Co., Ltd., where he continues to advance research in genetic screening technologies. His work has the potential to revolutionize early detection methods for lung carcinoma, significantly impacting patient outcomes.

Collaborations

Ruiqin has collaborated with notable colleagues, including Changming Cheng and Chao Yang, to further enhance the research and application of genetic markers in clinical settings.

Conclusion

Ruiqin Ma's innovative contributions to genetic screening for lung carcinoma highlight the importance of early detection in improving patient care. His work not only advances scientific knowledge but also offers practical solutions for widespread health challenges.